Treatment of brain metastases

Journal of Clinical Oncology

Volumn 33, Issue 30, 2015, Pages 3475-3484

  Lin, Xuling ^a   DeAngelis, Lisa M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; CORTICOSTEROID;

ANTICOAGULANT THERAPY; BRAIN METASTASIS; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; HUMAN; IMMUNOTHERAPY; PATIENT CARE; PRIMARY TUMOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOLID TUMOR; STEREOTACTIC RADIOSURGERY; BRAIN NEOPLASMS; SECONDARY;

BRAIN NEOPLASMS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84945176534     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.60.9503     Document Type: Review

References (121)

1. Posner JB, Chernik NL: Intracranial metastases from systemic cancer. Adv Neurol 19:579-592, 1978
2. Takakura K: Metastatic Tumors of the Central Nervous System. Tokyo, Japan, Igaku-Shoin, 1982
3. Stewart BW, Wild C, International Agency for Research on Cancer, et al: World Cancer Report 2014. Lyon, France, International Agency for Research on Cancer, 2014
4. Nussbaum ES, Djalilian HR, Cho KH, et al: Brain metastases: Histology, multiplicity, surgery, and survival. Cancer 78:1781-1788, 1996
5. Lai R, Dang CT, Malkin MG, et al: The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 101:810-816, 2004
6. Omuro AM, Kris MG, Miller VA, et al: High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 103: 2344-2348, 2005
7. Gaspar LE, Scott C, Murray K, et al: Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 47:1001-1006, 2000
8. Lutterbach J, Bartelt S, Ostertag C: Longterm survival in patients with brain metastases. J Cancer Res Clin Oncol 128:417-425, 2002
9. Kaal EC, Niël CG, Vecht CJ: Therapeutic management of brain metastasis. Lancet Neurol 4:289-298, 2005
10. Sperduto PW, Kased N, Roberge D, et al: Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30:419-425, 2012
11. Rwigema JC, Wegner RE, Mintz AH, et al: Stereotactic radiosurgery to the resection cavity of brain metastases: A retrospective analysis and literature review. Stereotact Funct Neurosurg 89: 329-337, 2011
12. Iorio-Morin C, Masson-Cote L, Ezahr Y, et al: Early Gamma Knife stereotactic radiosurgery to the tumor bed of resected brain metastasis for improved local control. J Neurosurg 121:69-74, 2014 (suppl)
13. Robinet G, Thomas P, Breton JL, et al: Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancérologie (GFPC) Protocol 95-1. Ann Oncol 12:59-67, 2001
14. Lee DH, Han JY, Kim HT, et al: Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first: Result of a randomized pilot study. Cancer 113:143-149, 2008
15. Kim KH, Lee J, Lee JI, et al: Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases? Lung Cancer 68:258-263, 2010
16. Patchell RA, Tibbs PA, Walsh JW, et al: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494-500, 1990
17. Ryken TC, McDermott M, Robinson PD, et al: The role of steroids in the management of brain metastases: A systematic review and evidence-based clinical practice guideline. J Neurooncol 96: 103-114, 2010
18. Soffietti R, Cornu P, Delattre JY, et al: EFNS guidelines on diagnosis and treatment of brain metastases: Report of an EFNS Task Force. Eur J Neurol 13:674-681, 2006
19. Vecht CJ, Hovestadt A, Verbiest HB, et al: Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: A randomized study of doses of 4, 8, and 16 mg per day. Neurology 44:675-680, 1994
20. Hempen C, Weiss E, Hess CF: Dexamethasone treatment in patients with brain metastases and primary brain tumors: Do the benefits outweigh the side-effects? Support Care Cancer 10:322-328, 2002
21. Oberndorfer S, Schmal T, Lahrmann H, et al: The frequency of seizures in patients with primary brain tumors or cerebral metastases: An evaluation from the Ludwig Boltzmann Institute of Neuro-Oncology and the Department of Neurology, Kaiser Franz Josef Hospital, Vienna [in German]. Wien Klin Wochenschr 114:911-916, 2002
22. Glantz MJ, Cole BF, Friedberg MH, et al: A randomized, blinded, placebo-controlled trial of dival-proex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology 46:985-991, 1996
23. North JB, Penhall RK, Hanieh A, et al: Phenytoin and postoperative epilepsy: A double-blind study. J Neurosurg 58:672-677, 1983
24. Forsyth PA, Weaver S, Fulton D, et al: Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci 30:106-112, 2003
25. Franceschetti S, Binelli S, Casazza M, et al: Influence of surgery and antiepileptic drugs on seizures symptomatic of cerebral tumours. Acta Neurochir (Wien) 103:47-51, 1990
26. Glantz MJ, Cole BF, Forsyth PA, et al: Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors-Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 54: 1886-1893, 2000
27. Heit JA, Silverstein MD, Mohr DN, et al: Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study. Arch Intern Med 160:809-815, 2000
28. Alvarado G, Noor R, Bassett R, et al: Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastases. Melanoma Res 22:310-315, 2012
29. Iorio A, Agnelli G: Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: A meta-analysis. Arch Intern Med 160:2327-2332, 2000
30. Schiff D, DeAngelis LM: Therapy of venous thromboembolism in patients with brain metastases. Cancer 73:493-498, 1994
31. Peak S, Abrey LE: Chemotherapy and the treatment of brain metastases. Hematol Oncol Clin North Am 20:1287-1295, 2006
32. Oechsle K, Bokemeyer C: Treatment of brain metastases from germ cell tumors. Hematol Oncol Clin North Am 25:605-613, 2011
33. Kristensen CA, Kristjansen PE, Hansen HH: Systemic chemotherapy of brain metastases from small-cell lung cancer: A review. J Clin Oncol 10: 1498-1502, 1992
34. Grossi F, Scolaro T, Tixi L, et al: The role of systemic chemotherapy in the treatment of brain metastases from small-cell lung cancer. Crit Rev Oncol Hematol 37:61-67, 2001
35. Shah SP, Morin RD, Khattra J, et al: Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461:809-813, 2009
36. Campbell PJ, Yachida S, Mudie LJ, et al: The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467:1109-1113, 2010
37. Lockman PR, Mittapalli RK, Taskar KS, et al: Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res 16:5664-5678, 2010
38. Pitz MW, Desai A, Grossman SA, et al: Tissue concentration of systemically administered antineoplastic agents in human brain tumors. J Neurooncol 104:629-638, 2011
39. Neuhaus T, Ko Y, Muller RP, et al: A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. Br J Cancer 100:291-297, 2009
40. Guerrieri M, Wong K, Ryan G, et al: A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. Lung Cancer 46:107-111, 2004
41. Krown SE, Niedzwiecki D, Hwu WJ, et al: Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: High rate of thromboembolic events (CALGB 500102). Cancer 107:1883-1890, 2006
42. Cocconi G, Lottici R, Bisagni G, et al: Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. Cancer Invest 8:327-334, 1990
43. Franciosi V, Cocconi G, Michiara M, et al: Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: A prospective study. Cancer 85: 1599-1605, 1999
44. Ekenel M, Hormigo AM, Peak S, et al: Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol 85:223-227, 2007
45. Lassman AB, Abrey LE, Shah GD, et al: Systemic high-dose intravenous methotrexate for central nervous system metastases. J Neurooncol 78:255-260, 2006
46. Antonadou D, Paraskevaidis M, Sarris G, et al: Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 20:3644-3650, 2002
47. Agarwala SS, Kirkwood JM, Gore M, et al: Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study. J Clin Oncol 22:2101-2107, 2004
48. Verger E, Gil M, Yaya R, et al: Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: A phase II randomized trial. Int J Radiat Oncol Biol Phys 61:185-191, 2005
49. Cameron D, Casey M, Press M, et al: A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat 112:533-543, 2008
50. Bachelot T, Romieu G, Campone M, et al: Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): A single-group phase 2 study. Lancet Oncol 14:64-71, 2013
51. Lin NU, Diéras V, Paul D, et al: Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15:1452-1459, 2009
52. Shimato S, Mitsudomi T, Kosaka T, et al: EGFR mutations in patients with brain metastases from lung cancer: Association with the efficacy of gefitinib. Neuro Oncol 8:137-144, 2006
53. Welsh JW, Komaki R, Amini A, et al: Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 31:895-902, 2013
54. Grommes C, Oxnard GR, Kris MG, et al: "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 13:1364-1369, 2011
55. Long GV, Trefzer U, Davies MA, et al: Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial. Lancet Oncol 13:1087-1095, 2012
56. Dummer R, Goldinger SM, Turtschi CP, et al: Vemurafenib in patients with BRAF(V600) mutationpositive melanoma with symptomatic brain metastases: Final results of an open-label pilot study. Eur J Cancer 50:611-621, 2014
57. Chevreau C, Ravaud A, Escudier B, et al: A phase II trial of sunitinib in patients with renal cell cancer and untreated brain metastases. Clin Genitourin Cancer 12:50-54, 2014
58. Socinski MA, Langer CJ, Huang JE, et al: Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 27:5255-5261, 2009
59. Khasraw M, Holodny A, Goldlust SA, et al: Intracranial hemorrhage in patients with cancer treated with bevacizumab: The Memorial Sloan-Kettering experience. Ann Oncol 23:458-463, 2012
60. Falchook GS, Moulder SL, Wheler JJ, et al: Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer. Ann Oncol 24:3004-3011, 2013
61. Falchook GS, Naing A, Hong DS, et al: Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer. Oncotarget 4:118-127, 2013
62. González-Cao M, Viteri S, Díaz-Lagares A, et al: Preliminary results of the combination of bevacizumab and weekly paclitaxel in advanced melanoma. Oncology 74:12-16, 2008
63. Mountzios G, Emmanouilidis C, Vardakis N, et al: Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: A phase II multicenter study of the Hellenic Oncology Research Group. Lung Cancer 77:146-150, 2012
64. Margolin K, Ernstoff MS, Hamid O, et al: Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial. Lancet Oncol 13:459-465, 2012
65. Drappatz J, Brenner A, Wong ET, et al: Phase I study of GRN1005 in recurrent malignant glioma. Clin Cancer Res 19:1567-1576, 2013
66. Cairncross JG, Kim JH, Posner JB: Radiation therapy for brain metastases. Ann Neurol 7:529-541, 1980
67. Chatani M, Teshima T, Hata K, et al: Whole brain irradiation for metastases from lung carcinoma: A clinical investigation. Acta Radiol Oncol 24:311-314, 1985
68. Hoskin PJ, Crow J, Ford HT: The influence of extent and local management on the outcome of radiotherapy for brain metastases. Int J Radiat Oncol Biol Phys 19:111-115, 1990
69. DeAngelis LM, Posner JB, Posner JB: Neurologic Complications of Cancer (ed 2). New York, NY, Oxford University Press, 2009
70. Gerrard GE, Prestwich RJ, Edwards A, et al: Investigating the palliative efficacy of whole-brain radiotherapy for patients with multiple-brain metastases and poor prognostic features. Clin Oncol (R Coll Radiol) 15:422-428, 2003
71. Tsao MN, Lloyd N, Wong RK, et al: Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases. Cochrane Database Syst Rev 4:CD003869, 2012
72. Young DF, Posner JB, Chu F, et al: Rapidcourse radiation therapy of cerebral metastases: Results and complications. Cancer 34:1069-1076, 1974
73. DeAngelis LM, Currie VE, Kim JH, et al: The combined use of radiation therapy and lonidamine in the treatment of brain metastases. J Neurooncol 7:241-247, 1989
74. Eyre HJ, Ohlsen JD, Frank J, et al: Randomized trial of radiotherapy versus radiotherapy plus metronidazole for the treatment metastatic cancer to brain: A Southwest Oncology Group study. J Neurooncol 2:325-330, 1984
75. Komarnicky LT, Phillips TL, Martz K, et al: A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int J Radiat Oncol Biol Phys 20:53-58, 1991
76. Mehta MP, Rodrigus P, Terhaard CH, et al: Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 21: 2529-2536, 2003
77. Phillips TL, Scott CB, Leibel SA, et al: Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: Report of RTOG trial 89-05. Int J Radiat Oncol Biol Phys 33:339-348, 1995
78. Suh JH, Stea B, Nabid A, et al: Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol 24:106-114, 2006
79. Li J, Bentzen SM, Renschler M, et al: Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol 25:1260-1266, 2007
80. Aoyama H, Tago M, Kato N, et al: Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys 68:1388-1395, 2007
81. Jatoi A, Kahanic SP, Frytak S, et al: Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients: Preliminary results and suggestions for future study designs. Support Care Cancer 13:66-69, 2005
82. Brown PD, Pugh S, Laack NN, et al: Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: A randomized, double-blind, placebo-controlled trial. Neuro Oncol 15:1429-1437, 2013
83. Gondi V, Tome WA, Marsh J, et al: Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: Safety profile for RTOG 0933. Radiother Oncol 95:327-331, 2010
84. Gondi V, Pugh SL, Tome WA, et al: Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): A phase II multi-institutional trial. J Clin Oncol 32:3810-3816, 2014
85. Suh JH: Hippocampal-avoidance whole-brain radiation therapy: A new standard for patients with brain metastases? J Clin Oncol 32:3789-3791, 2014
86. Delattre JY, Krol G, Thaler HT, et al: Distribution of brain metastases. Arch Neurol 45:741-744, 1988
87. Kondziolka D, Patel A, Lunsford LD, et al: Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 45:427-434, 1999
88. Andrews DW, Scott CB, Sperduto PW, et al: Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet 363:1665-1672, 2004
89. Aoyama H, Shirato H, Tago M, et al: Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial. JAMA 295:2483-2491, 2006
90. Chang EL, Wefel JS, Hess KR, et al: Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial. Lancet Oncol 10:1037-1044, 2009
91. Tsao M, Xu W, Sahgal A: A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases. Cancer 118: 2486-2493, 2012
92. Hall MD, McGee JL, McGee MC, et al: Cost-effectiveness of stereotactic radiosurgery with and without whole-brain radiotherapy for the treatment of newly diagnosed brain metastases. J Neurosurg 121:84-90, 2014 (suppl)
93. Yamamoto M, Serizawa T, Shuto T, et al: Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): A multi-institutional prospective observational study. Lancet Oncol 15: 387-395, 2014
94. Shaw E, Scott C, Souhami L, et al: Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 47:291-298, 2000
95. Yomo S, Hayashi M: The efficacy and limitations of stereotactic radiosurgery as a salvage treatment after failed whole brain radiotherapy for brain metastases. J Neurooncol 113:459-465, 2013
96. Kurtz G, Zadeh G, Gingras-Hill G, et al: Salvage radiosurgery for brain metastases: Prognostic factors to consider in patient selection. Int J Radiat Oncol Biol Phys 88:137-142, 2014
97. Marks JE, Wong J: The risk of cerebral radionecrosis in relation to dose, time and fractionation: A follow-up study. Prog Exp Tumor Res 29: 210-218, 1985
98. Minniti G, Clarke E, Lanzetta G, et al: Stereotactic radiosurgery for brain metastases: Analysis of outcome and risk of brain radionecrosis. Radiat Oncol 6:48 2011
99. Mitsuya K, Nakasu Y, Horiguchi S, et al: Perfusion weighted magnetic resonance imaging to distinguish the recurrence of metastatic brain tumors from radiation necrosis after stereotactic radiosurgery. J Neurooncol 99:81-88, 2010
100. Glantz MJ, Burger PC, Friedman AH, et al: Treatment of radiation-induced nervous system injury with heparin and warfarin. Neurology 44:2020-2027, 1994
101. Boothe D, Young R, Yamada Y, et al: Bevacizumab as a treatment for radiation necrosis of brain metastases post stereotactic radiosurgery. Neuro Oncol 15:1257-1263, 2013
102. Levin VA, Bidaut L, Hou P, et al: Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 79:1487-1495, 2011
103. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al: Treatment of single brain metastasis: Radiotherapy alone or combined with neurosurgery? Ann Neurol 33:583-590, 1993
104. Mintz AH, Kestle J, Rathbone MP, et al: A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 78:1470-1476, 1996
105. Hart MG, Grant R, Walker M, et al: Surgical resection and whole brain radiation therapy versus whole brain radiation therapy alone for single brain metastases. Cochrane Database Syst Rev 1:CD003292, 2005
106. Patchell RA, Tibbs PA, Regine WF, et al: Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA 280:1485-1489, 1998
107. Rades D, Bohlen G, Pluemer A, et al: Stereotactic radiosurgery alone versus resection plus whole-brain radiotherapy for 1 or 2 brain metastases in recursive partitioning analysis class 1 and 2 patients. Cancer 109:2515-2521, 2007
108. Muacevic A, Wowra B, Siefert A, et al: Microsurgery plus whole brain irradiation versus Gamma Knife surgery alone for treatment of single metastases to the brain: A randomized controlled multicentre phase III trial. J Neurooncol 87:299-307, 2008
109. Schoggl A, Kitz K, Reddy M, et al: Defining the role of stereotactic radiosurgery versus microsurgery in the treatment of single brain metastases. Acta Neurochir (Wien) 142:621-626, 2000
110. Roos DE, Smith JG, Stephens SW: Radiosurgery versus surgery, both with adjuvant whole brain radiotherapy, for solitary brain metastases: A randomised controlled trial. Clin Oncol (R Coll Radiol) 23:646-651, 2011
111. Kocher M, Soffietti R, Abacioglu U, et al: Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study. J Clin Oncol 29:134-141, 2011
112. Linskey ME, Andrews DW, Asher AL, et al: The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. J Neurooncol 96:45-68, 2010
113. Gans JH, Raper DM, Shah AH, et al: The role of radiosurgery to the tumor bed after resection of brain metastases. Neurosurgery 72:317-325, 2013
114. Brennan C, Yang TJ, Hilden P, et al: A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases. Int J Radiat Oncol Biol Phys 88:130-136, 2014
115. van der Ree TC, Dippel DW, Avezaat CJ, et al: Leptomeningeal metastasis after surgical resection of brain metastases. J Neurol Neurosurg Psychiatry 66:225-227, 1999
116. Bindal AK, Bindal RK, Hess KR, et al: Surgery versus radiosurgery in the treatment of brain metastasis. J Neurosurg 84:748-754, 1996
117. O'Neill BP, Iturria NJ, Link MJ, et al: A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases. Int J Radiat Oncol Biol Phys 55:1169-1176, 2003
118. Kamp MA, Dibue M, Santacroce A, et al: The tumour is not enough or is it? Problems and new concepts in the surgery of cerebral metastases. Ecancermedicalscience 7:306 2013
119. Yoo H, Kim YZ, Nam BH, et al: Reduced local recurrence of a single brain metastasis through microscopic total resection. J Neurosurg 110:730-736, 2009
120. Obermueller T, Schaeffner M, Gerhardt J, et al: Risks of postoperative paresis in motor eloquently and non-eloquently located brain metastases. BMC Cancer 14:21 2014
121. Brown PD, Asher AL, Ballman KV, et al: NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. J Clin Oncol 33:4s, 2015 (suppl; abstr LBA4)